The Ernst Moritz Arndt University Greifswald is one of the oldest universities in Germany and was founded in 1456. The University Medicine Greifswald of the Ernst Moritz Arndt University Greifswald is one of the biggest hospitals in northern Germany with 21 clinics, 19 institutes and further research centres. The hospital has 926 beds and treated, in 2011, 150,000 patients. Within the University Medicine,
the Department of Gynaecology has a long standing experience in clinical practice as well as translational research in cervical cancer, taking part in many phase II and III clinical trials for gynecological malignancies and cervical cancer in particular.
Our institution is linked to the major national and international trial groups (e.g. EORTC,  AGO- and NOGGO-which study center is established in our department,)
The research laboratory conducts different epigenetic and genetic research in the field of gynaecology and oncology. The laboratory has excellent facility for advanced high level genomic, epigenomic analysis. The department of Gynaecology and Obstetrics is since 2004 part of  the international multicentric tumor bank ovarian cancer network (TOC, Banking  Cervical Cancer is established  since 2011.
Our center is one of the key partners in the FP7 GANNET 53 project.


Role within the project

As the leader of WP4, EMAUG will be in charge of the prospective assessment of active pathways and genetic mutations in cervical cancer patients. In order to achieve this WP, EMAUG will set up clinical protocol and SOPs for sample collection.


Description of key people involved in the project

  • Alexander Mustea, MD; PhD, Professor of Gynaecology and Obstetrics and Vice-Head of the Department of Gynaecology and Obstetrics at the University Medicine in Greifswald (, Head of the Gynecological Cancer Center has a striking clinical experience in gynecological oncology and is experienced in developing international tumor banking Network (TOC- Network) for gynaecological tumors. He is active in scientific research being the initiator and leader of several phase II to Phase III clinical trials. He just finished a multi-centric NOGGO Phase II Trial in advanced cervical cancer (ASCO, 2011). He was involved in OVCAD consortium and is a part of GANNET53 consortium.

  • Dominique Koensgen, MD; PhD, Ass. Prof., is a physician working in the field of cervical cancer. She is leading the Tumorbanking for Ovarian-, Cervical- and Endometrial- Cancer and the translational research within the group. She was involved in OVCAD consortium and is a part of GANNET53consortium.

  • Daniela Brunnert, Post-Doc, is a Biologist with striking experience in research focused on prognostic and predictive factors in gynecological malignancies, and in particular for ovarian cancer. She is involved in GANNET53 consortium.